Medicines – Open-House biologic rebate agreements for denosumab 2025–31

Summary

The tender concerns Open-House rebate agreements for biologic medicines containing denosumab. Any suitable pharmaceutical company may join on uniform terms; there are no individual negotiations and no exclusivity is granted. The contract term is up to 24 months starting on 01/12/2025, and accession is possible at any time during the contract period. The exact participation and contract conditions must be checked in the tender documents.